Related Experiment Videos
Use of ciprofloxacin in developing countries
1St. Luke's Hospital, Bradford, Yorkshire, United Kingdom.
Insights
Ciprofloxacin is a safe and effective antibiotic for treating pediatric infections in developing nations, addressing rising antibiotic resistance. Its use is crucial as other treatment options diminish.
Area of Science:
- Infectious Diseases
- Pediatric Medicine
- Antimicrobial Resistance
Background:
- Rising antibiotic resistance in developing nations due to demographic and economic pressures.
- Diminishing empirical treatment options for pediatric infections.
- Increasing significance of ciprofloxacin for pediatric infections.
Purpose of the Study:
- Describe resistance levels in enteric pathogens.
- Evaluate ciprofloxacin's efficacy and safety in pediatric infections (shigellosis, cholera, E. coli gastroenteritis).
- Present findings on invasive salmonellosis and meningococcal disease chemoprophylaxis.
Main Methods:
- Review of existing studies on ciprofloxacin efficacy and safety in children.
- Analysis of resistance patterns in enteric pathogens.
- Inclusion of data from a large study on invasive salmonellosis in African children.
Main Results:
- Ciprofloxacin demonstrated comparable efficacy and safety in children to adults for gastrointestinal infections.
- Confirmed ciprofloxacin as a safe and effective treatment for pediatric infections in developing countries.
- Highlighted ciprofloxacin's role in managing multidrug-resistant invasive diseases.
Conclusions:
- Ciprofloxacin is a safe and effective therapeutic option for children in developing countries.
- Urgent need to prevent fluoroquinolone misuse and curb antibiotic resistance development.
- Prioritization for pharmaceutical industry and regulatory bodies in developing nations.
Background:
The demographic and subsequent economic pressures in developing nations have contributed to the increasing levels of antibiotic resistance among both commensal flora and pathogenic bacteria. As empirical options are diminishing daily, the role of ciprofloxacin in pediatric infections is becoming increasingly significant.
Objective:
The levels of resistance among various enteric pathogens are described, and the efficacy and safety of ciprofloxacin in treating infections such as shigellosis, cholera and Escherichia coli gastroenteritis are discussed. The findings of a large study of invasive salmonellosis in children in rural Africa are briefly presented, including the role of ciprofloxacin in multiresistant invasive disease. In addition the role of ciprofloxacin as a chemoprophylactic agent in the control of meningococcal disease is discussed.
Results:
The efficacy and safety of ciprofloxacin in children were found to be similar to those observed in adults for gastrointestinal infectious diseases. Overall the data presented confirm that ciprofloxacin is a safe and efficacious agent for use in children in the developing world.
Conclusion:
Ciprofloxacin has been shown to be safe and efficacious in children in developing countries. Subsequently a priority for both the pharmaceutical industry and regulatory authorities in developing nations is to prevent fluoroquinolone misuse and development of antibiotic resistance.